RxDoctor Payments Data

Maria Fernandez

Family Medicine · Reno, NVNPI 1710475538

Payments from drug & device makers

$379in general payments, 2019–2025

Across 13 payments — averaging $29.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$112
  • Gilead$107
  • Amgen$44
  • GSK$32
  • Merck$22
  • Hologic Sales And Service, LLC$21
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie4$112
Gilead1$107
Amgen(2 entities)2$44
GSK2$32
Merck1$22
Hologic Sales And Service, LLC1$21
Sanofi Pasteur Inc.1$21
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$379 in reported general payments places this provider in the 50th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$698
Medicare patients
19
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$58,256
OzempicSemaglutide45$55,981
TrulicityDulaglutide20$32,797
EliquisApixaban25$24,853
SynjardyEmpagliflozin/Metformin Hcl20$21,428
JanuviaSitagliptin Phosphate12$18,667
TradjentaLinagliptin26$18,389
AbrysvoRsv Vacc, Pref A And Pref B/Pf52$15,026
FarxigaDapagliflozin Propanediol16$14,620
ShingrixVaricella-Zoster Ge/As01b/Pf44$9,107
Breo ElliptaFluticasone/Vilanterol11$4,648
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,748
Atorvastatin Calcium275$2,635
Boostrix TdapDiphth,pertuss(Acell),tet Vac35$2,205
Rosuvastatin Calcium77$1,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$20$39,87977 claims
MerckJanuvia$22$18,66712 claims
GSKShingrix, Breo Ellipta$32$13,75455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →